Roche at ASCO GI 2018, 18-20 Jan, San Francisco, CA
Meet Roche at ASCO GI 2018
The Gastrointestinal (GI) Cancers Symposium is a multidisciplinary and specialised oncology event designed for healthcare professionals and the research community. This three-day meeting will cover emerging science as well as innovative therapy options for malignancies of the oesophagus, stomach, pancreas, small bowel, colon, rectum, and anus.
ASCO GI 2018 - Jan 18-20, San Francisco, CA
Discover Roche’s highlights from this year’s meeting on this page
Latest on Medically from ASCO GI 2018
ASCO GI 2018 poster - MORPHEUS: A Phase Ib/II Multi-trial Platform Evaluating the Efficacy and Safety of Cancer Immunotherapy–based Combinations in Patients with Gastric or Pancreatic Cancer
The MORPHEUS-GC phase Ib/II study will enroll patients with advanced unresectable or metastatic gastric cancer who have not received prior chemotherapy (chemo) or have progressed on platinum- or fluoropyrimidine-based chemo. The MORPHEUS-PDAC phase Ib/II study will enroll patients with metastatic pancreatic ductal adenocarcinoma who have progressed on prior chemo. Primary endpoints are investigator-assessed ORR per RECIST v1.1 and safety. Secondary endpoints include PFS, OS, DCR and DOR. Multiple exploratory biomarkers will also be examined.
ASCO GI 2018 POSTER- A Phase Ib study of safety and clinical activity of atezolizumab and ▼cobimetinib in patients with metastatic colorectal cancer
Results from the phase Ib study of atezolizumab + ▼cobimetinib demonstrated a tolerable safety profile and improvements in OS vs those reported with SOC in heavily pretreated patients with mCRC. Objective responses observed in patients with MSS/MSI-low mCRC were durable, suggesting benefit of this novel combination in a patient population refractory to immune therapies.
ASCO GI 2018 POSTER-Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC)
This retrospective exploratory subgroup analysis of 2 pivotal phase 3 studies was conducted to investigate the effect tumor location on of bevacizumab efficacy. Similar PFS and OS improvements were observed when patients were stratified according to baseline characteristics.